Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update

Endocrinol Diabetes Nutr (Engl Ed). 2018 Dec;65(10):611-624. doi: 10.1016/j.endinu.2018.08.004. Epub 2018 Oct 23.
[Article in English, Spanish]

Abstract

Type 2 diabetes mellitus (DM2) has become a problem of global dimensions by their high and growing prevalence worldwide and the personal and economic costs associated with it. Correct treatment can reduce mortality and associated complications. New concepts have recently been included in routine clinical practice and have changed the algorithm of DM2 pharmacological therapy. Therefore, the Spanish Society of Diabetes (SED) entrusted to the Working Group of Consensus and Clinical Guidelines an update of the 2010 document Recommendations for Pharmacological Treatment of Hyperglycemia in Diabetes type2. Novel aspects include nine characteristics to describe each drug group: efficiency, the risk of hypoglycemia, effects on body weight, the demonstrated effect in cardiovascular risk, nephroprotection, limitation of use in renal insufficiency, the rate of secondary effects, complexity and costs. Additionally, the document details combination options, and develop the start and adjustment of available injectable therapies.

Keywords: Cardiovascular risk; Complejidad; Complexity; Cost; Coste; Diabetes tipo 2; Hipoglucemia; Hypoglycaemia; Nefroprotección; Nephroprotection; Riesgo cardiovascular; Tratamiento; Treatment; Type 2 diabetes.

Publication types

  • Practice Guideline

MeSH terms

  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetic Cardiomyopathies / prevention & control
  • Diabetic Nephropathies / prevention & control
  • Drug Costs
  • Drug Therapy, Combination
  • Glycated Hemoglobin / analysis
  • Humans
  • Hyperglycemia / drug therapy*
  • Hyperglycemia / etiology
  • Hypoglycemia / chemically induced
  • Hypoglycemia / prevention & control
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / classification
  • Hypoglycemic Agents / economics
  • Hypoglycemic Agents / therapeutic use*

Substances

  • Glycated Hemoglobin A
  • Hypoglycemic Agents